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https://doi.org/10.1016/j.celrep.2020.108232SUMMARYT follicular helper (Tfh) cells are crucial for the establishment of germinal centers (GCs) and potent antibody
responses. Nevertheless, the T cell-intrinsic factors that are required for the maintenance of already-estab-
lished Tfh cells and GCs remain largely unknown. Here, we use temporally guided gene ablation in CD4+
T cells to dissect the contributions of the Tfh-associated chemokine receptor CXCR5 and the transcription
factor Bcl6. Induced ablation of Cxcr5 has minor effects on the function of established Tfh cells, and
Cxcr5-ablated cells still exhibit most of the features of CXCR5+ Tfh cells. In contrast, continued Bcl6 expres-
sion is critical to maintain the GC Tfh cell phenotype and also the GC reaction. Importantly, Bcl6 ablation dur-
ing acute viral infection results in the transdifferentiation of established Tfh into Th1 cells, thus highlighting
the plasticity of Tfh cells. These findings have implications for strategies that boost or restrain Tfh cells
and GCs in health and disease.INTRODUCTION
T follicular helper (Tfh) cells are critically important for providing
help to B cells for potent antibody responses (Crotty, 2019; Vi-
nuesa et al., 2016). Tfh cells are characterized by the expression
of the chemokine receptor CXCR5 and the transcriptional
repressor Bcl6. In addition, they express several co-stimulatory
molecules such as inducible T cell co-stimulator (ICOS),
CD40L, and B- and T-lymphocyte attenuator (BTLA) and inhibi-
tory receptors such as programmed cell death protein-1 (PD-1)
that allow for close interactions with B cells. Furthermore, Tfh
cells produce cytokines such as interleukin-4 (IL-4) and IL-21
that instruct B cell class switching and survival.
Tfh cell differentiation is characterized by a multistep differen-
tiation process that involves sequential interactions with den-
dritic cells (DCs) and B cells in distinct micro-anatomical loca-
tions, ultimately leading to the establishment of germinal
centers (GCs), in which potent antibodies are generated (Crotty,
2019; Qi, 2016; Vinuesa et al., 2016). The induction of CXCR5-
and Bcl6-expressing early Tfh cells from naive CD4+ T cell pre-
cursors is mediated by DCs, which at this stage are independent
of cognate interactions with B cells (Baumjohann et al., 2011;This is an open access article undGoenka et al., 2011). Bcl6 acts as a transcriptional repressor
that restricts the expression of inappropriate genes and alterna-
tive fates in activated CD4+ T cells, thus promoting Tfh cell differ-
entiation (Hatzi et al., 2015; Johnston et al., 2009; Liu et al., 2016;
Nurieva et al., 2009; Yu et al., 2009). While the ensuing migration
of these activated CD4+ T cells toward the T-B cell border and
follicles is guided by the chemokine receptor CXCR5, simulta-
neous downregulation of the chemokine receptor CCR7, which
is highly expressed on naive T cells, is required to enable acti-
vated T cells to re-localize to the T-B zone border and to enter
the follicle andGC (Ansel et al., 1999; Arnold et al., 2007; Hardtke
et al., 2005; Haynes et al., 2007; Junt et al., 2005). Interestingly,
some CXCR5-deficient T helper cells have been observed in B
cell areas in some of these studies, while in others they have
not. The cause of these contradictory observations remains un-
clear. Localized within GCs, mature GC Tfh cells express the
highest levels of CXCR5 and Bcl6 among CD4+ T cells.
Continued interactions between antigen-presenting cells, in
particular B cells, and Tfh cells are required to maintain the Tfh
cell phenotype and GC responses (Baumjohann et al., 2013b;
Deenick et al., 2010). However, while the T cell-intrinsic factors
that are required for the initial steps of Tfh cell differentiationCell Reports 33, 108232, October 6, 2020 ª 2020 The Authors. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Tfh Cells Continue to Express Tfh
Cell Markers upon Induced Cxcr5 Ablation
(A) Schematic representation of the experimental
protocol for the analysis of the impact of induced
CD4+ T cell-specific ablation of Cxcr5 after NP-
KLH/alum immunization.
(B) Flow cytometry of CD4+ T cells from draining
lymph nodes of tamoxifen-treated Cd4-CreERT2+
Cxcr5+/+ and Cd4-CreERT2+ Cxcr5fl/fl mice,
referred to as iCxcr5+/+ and iCxcr5D/D, respec-
tively, analyzed on day 10 after immunization. Cells
were pre-gated as live CD4+CD44hiCD19 lym-
phocytes. Gate frequencies indicate the percent-
age of CXCR5–PD-1hi cells, CXCR5hiPD-1hi GC Tfh
cells, and CXCR5+PD-1lo/int Tfh cells (upper panel)
or CXCR5Bcl6hi cells and CXCR+Bcl6hi GC Tfh
cells (lower panel). Right, quantification of the re-
sults; each symbol represents an individual mouse
(n = 4–6).
(C) Quantification of CXCR5–PD-1hi and CXCR5+
Tfh cells from mice treated as in (B), measured on
day 10, 14 and 28 (n = 4–6).
(D) Flow cytometry and quantification of PD-
1hiBcl6hi CD4+ T cells in the draining lymph nodes
of mice on day 10 after immunization as in (B) (n =
4–6).
**p < 0.01 two-tailed nonparametric Mann-Whit-
ney test (B–D); means ± SEMs in (B)–(D). See also
Figure S1.
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OPEN ACCESShave been investigated in more detail (Crotty, 2019; Vinuesa
et al., 2016), it remains largely unknown whether and how
different T cell-expressed chemokine receptors and transcrip-
tion factors are also required for the maintenance of already es-
tablished Tfh cells, in part due to the lack of appropriate experi-
mental systems. Here, we established a system that allowed us
to ablate Cxcr5 and Bcl6 specifically in CD4+ T cells in a tempo-
rally controlledmanner to systematically test the requirements of
these two factors for Tfh cell and GC maintenance. We found2 Cell Reports 33, 108232, October 6, 2020that while CXCR5 Tfh cells kept most
of the Tfh cell features and functions,
Bcl6 was strictly required for the mainte-
nance of Tfh cell identity by preventing
the transdifferentiation into Th1 cells in
an acute viral infection model. These
functional insights not only emphasize
the high degree of plasticity of Tfh cells
but they also give indications about how
ongoing GC reactions may be modulated
in different disease settings.
RESULTS
Tfh Cells Retain B Cell Helper
Capabilities upon Induced Cxcr5
Ablation
To investigate the impact of a loss of
CXCR5 expression in preexisting Tfh
cells, we crossed mice bearing an induc-
ible Cd4-Cre-ERT2 allele to mice con-taining loxP-flanked Cxcr5 alleles to generate compound mice
in which Cxcr5 can be deleted specifically in CD4+ T cells
upon tamoxifen application (designated as iCxcr5D/D mice) (Fig-
ure 1A). Tamoxifen application on days 3 and 4 after subcu-
taneous (s.c.) hock immunization with nitrophenylacetyl conju-
gated to keyhole limpet hemocyanin (NP-KLH) in alum
resulted in an almost complete absence of CXCR5 protein in
CD4+ T cells from iCxcr5D/D mice that were analyzed on day
10 after immunization (Figure 1B). iCxcr5+/+ mice that
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Figure 2. Cxcr5-Ablated Tfh Cells Retain B Cell Helper Capabilities
(A) Schematic representation of the experimental protocol for the analysis of the impact of induced CD4+ T cell-specific ablation of Cxcr5 after NP-KLH/alum
immunization.
(B) Flow cytometry of B cells from draining lymph nodes of tamoxifen-treated Cd4-CreERT2+Cxcr5+/+ and Cd4-CreERT2+Cxcr5fl/fl mice, referred to as iCxcr5+/+
and iCxcr5D/D, respectively, analyzed on day 10 after immunization. Cells were pre-gated as live CD19+CD4– lymphocytes. Gate frequencies indicate the per-
centage of IgDloCD95hi GC B cells. Right, quantification of the results; each symbol represents an individual mouse (n = 4–6).
(C) Flow cytometry and quantification of NP-specific and IgG1+ GC B cells as in (B). the gate frequencies indicate the percentage of IgG1+NP, IgG1+NP+, and
IgG1NP+ GC B cells.
(D) Ratio of GC B cells with a CXCR4hiCD86lo dark zone (DZ) and CXCR4loCD86hi light zone (LZ) phenotype in the draining lymph nodes of mice as in (B).
(E–G) Quantification of (E) GCB cell numbers, (F) NP+GCBcells, and (G) IgG1+GCBcells frommice as in (B), measured on days 10, 14, and 28 after immunization
(n = 4–6).
*p < 0.05, **p < 0.01 two-tailed nonparametric Mann-Whitney test (B–G); means + SEMs in (B)–(G). See also Figure S1.
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OPEN ACCESSexpressed one allele of Cd4-CreERT2 but lacked loxP-flanked
Cxcr5 alleles served as controls. CXCR5+ PD-1int (Tfh) and
CXCR5hiPD-1hi (GC Tfh) cell populations were both absent in
iCxcr5D/D mice, further highlighting the very efficient deletion
of Cxcr5 by Cd4-CreERT2 (Figure 1B). Interestingly, we
observed PD-1hi and Bcl6+ cell populations within the CXCR5
CD4+ T cell compartment in iCxcr5D/D mice that were not pre-
sent in iCxcr5+/+ control mice (Figure 1B). These populations
even persisted until days 14 and 28 after immunization without
a substantial decrease over time (Figure 1C). The observation
that Bcl6 and PD-1 double-positive cells were detectable at
similar frequencies in iCxcr5+/+ and iCxcr5D/D mice indicated
that these CXCR5 cells retained the expression of Tfh markers
associated with GC Tfh cells, with the exception of CXCR5 it-
self (Figure 1D).As GC B cells depend strongly on the presence of Tfh cells
(Baumjohann et al., 2013b), we additionally assessed the impact
of the induced deletion of Cxcr5 in CD4+ T cells on the B cell
response. In iCxcr5D/Dmice, the fraction of FashiIgDlo GC B cells
was reduced compared to iCxcr5+/+ control mice on day 10 (Fig-
ures 2A and 2B). NP-specific and immunoglobulin G1+ (IgG1+)
class-switched GCB cells were not diminished (Figure 2C). Pref-
erential GC B cell localization in the dark zone (DZ) of GCs was
also unaffected by the CD4+ T cell-specific Cxcr5 deletion, as
determined by the expression of the DZ and light zone (LZ)
markers CXCR4 and CD86, respectively (Figure 2D). GC B cells,
IgG1+ class-switched cells, and NP-specific GC B cells were
maintained over time until day 28 (Figures 2E–2G). Interestingly,
we observed a trend toward a higher abundance of class-
switched IgG1+ cells throughout the immune response, whichCell Reports 33, 108232, October 6, 2020 3
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OPEN ACCESSbecame more prominent by day 28 (Figure 2G). These findings
demonstrated that certain aspects of the GC response did not
depend on the continued presence of CXCR5 on the surface of
CD4+ T cells. When Cxcr5 ablation was induced at the peak of
the GC reaction on days 6 and 7 after immunization, similar ef-
fects on the maintenance of Tfh cell marker expression and
GC B cell helper capabilities were observed (Figure S1).
Induced Cxcr5 Deficiency Has Little Impact on the
Identity of Tfh Cells
To further explore the consequences ofCxcr5 ablation on estab-
lished Tfh cells, we next crossed theCd4-CreERT2+Cxcr5+/+ and
Cd4-CreERT2+Cxcr5fl/fl mice to animals bearing the lymphocytic
choriomeningitis virus (LCMV)-specific SMARTA (SM) T cell re-
ceptor (TCR) transgene and congenic Cd45 alleles. Naive
CD4+ T cells from these mice were adoptively transferred into
wild-type hosts, followed by intraperitoneal (i.p.) infection with
LCMV Armstrong to induce an acute viral infection (Figure 3A).
Tamoxifen was administered on days 3 and 4 and the phenotype
of the transferred SM cells was analyzed by flow cytometry on
day 10. In agreement with our findings from the immunization ex-
periments, we observed a population of CXCR5 iCxcr5D/D SM
cells that exhibited surface marker expression reminiscent of
Tfh cells with low levels of P-selectin glycoprotein ligand-1
(PSGL-1) and signaling lymphocytic activation molecule
(SLAM) (Figure 3B). To examine whether CXCR5-deficient Tfh
cells only kept a few Tfh cell markers or maintained an overall
Tfh-characteristic expression profile, we conducted RNA
sequencing (RNA-seq) of CD4+ T cells after subcutaneous NP-
KLH/alum immunization (Figure 3C). Cxcr5 ablation was induced
by tamoxifen gavage on days 3 and 4. On day 10 after immuni-
zation, CXCR5 Tfh (CD44hiCXCR5PD-1hiGITRlo) cells were
sorted from iCxcr5D/D mice together with Tfh
(CD44hiCXCR5+PD-1hiGITRlo) and non-Tfh (CD44hiCXCR5PD-
1loGITRlo) cells from control iCxcr5+/+ mice (Figure 3D). Sorted
cells were pre-gated on GITRlo cells to avoid contamination
with regulatory T (Treg) cells, which may also express PD-1.
This strategy also excluded T follicular regulatory (Tfr) cells. Tran-
scriptomic analysis revealed that the expression profile of
CXCR5 Tfh cells exhibited an extensive overlap with the profile
of CXCR5+ Tfh cells, thereby remaining clearly distinct from non-
Tfh cells (Figure 3E). Similar to their Cxcr5-sufficient Tfh cell
counterparts, CXCR5 Tfh cells showed characteristic expres-Figure 3. Induced Cxcr5 Deficiency Has Little Impact on the Identity o
(A) Schematic representation of the experimental protocol for the analysis of the i
after i.p. infection with LCMV Armstrong.
(B) Flow cytometry of splenocytes from tamoxifen-treated wild-type recipient mi
and Cd4-CreERT2+ Cxcr5fl/fl SM cells, followed by i.p. infection of recipients with
2CD19 lymphocytes. The gate frequencies indicate the percentage of CXCR5P
1hiSLAMhi Th1 cells and CXCR5+ or PSGL-1loSLAMlo Tfh cells. Right, quantificat
(C) Schematic representation of the experimental protocol for the analysis of the
immunization.
(D) Non-Tfh (CXCR5–PD-1GITRlo, n = 4) and Tfh cells (CXCR5+PD-1hiGITRlo, n =
iCxcr5D/D mice were sorted on day 10 after immunization for RNA-seq. Pre-gate
(E) Heatmap of the normalized expression of selected Th1 or Tfh genes (rows) in
(F) Principal-component analysis (PCA) of non-Tfh, Tfh, and CXCR5 Tfh cell trans
points delineate computed confidence ellipses with a 95% confidence level.
*p < 0.05, **p < 0.01 two-tailed nonparametric Mann-Whitney test (B); means ± Ssion patterns of co-receptors (high Pdcd1 and Icos), signaling
molecules (high Il6st), migratory molecules (high Sh2d2a; low
Selplg, Ccr7, and Ly6c2), and transcription factors (increased
Maf, Tox2, and Ascl2; decreased Klf2) (Figure 3E). Principal-
component analysis (PCA) using the 500 most variable genes
confirmed that the PD-1hi cells from iCxcr5D/D mice were tran-
scriptionally similar to Cxcr5-sufficient Tfh cells and differed
strongly from non-Tfh cells (Figure 3F). More important, we could
corroborate the largely unaltered identity of CXCR5 Tfh cells
also in our SM-based adoptive transfermodel, in which iCxcr5D/D
SM Tfh cells clearly shared a transcriptomic signature similar to
iCxcr5+/+ SM Tfh cells (data not shown). Likewise, the transcrip-
tomic signature of iCxcr5D/D SM Th1 cells tightly overlapped with
that of iCxcr5+/+ SM Th1 control cells (data not shown). In sum-
mary, these data showed that the transcriptional programming
of established Tfh cells did not depend on continued expression
of Cxcr5.
Continued T Cell-Specific Bcl6 Expression Is Critical for
GC Tfh and GC B Cell Maintenance
As we could show that the Tfh cell hallmark chemokine receptor
CXCR5, which historically helped to define the term ‘‘Tfh cells’’
(Ansel et al., 1999; Breitfeld et al., 2000; Schaerli et al., 2000),
was not required for the maintenance of the Tfh cell phenotype,
we next investigated the requirement of the Tfh cell master regu-
lator Bcl6 using our inducible-knockout system. To this end,
Bcl6fl/flmice,which allow for thedeletion of theBcl6DNA-binding
domain, were intercrossed with the aforementioned Cd4-Cre-
ERT2 strain. Efficient tamoxifen-induced deletion of Bcl6 was
confirmed on the genomic DNA and mRNA levels (Figures S2A
and S2B). We then analyzed the impact of tamoxifen-induced,
CD4+ T cell-specific Bcl6 ablation on the T and B cell response
after subcutaneous NP-KLH immunization (Figure 4A).We chose
two different time points of Bcl6 ablation when Tfh cells were
either already formed early on during the immune response
(tamoxifen gavage on days 3 and 4) or later when the GC
response was full blown (days 6 and 7). We observed a reduction
in the frequency of CXCR5+ PD-1int/lo (Tfh) CD4+ T cells afterBcl6
ablation, which was more pronounced for the early tamoxifen
time point (Figures 4B and S2C). There was also a significant
decrease in the frequency of CXCR5hiPD-1hi GCTfh cells in iBcl6-
D/D mice as compared to control iBcl6+/+ mice for both ablation
timepoints (Figures 4BandS2C). In linewith the lower expressionf Tfh Cells
mpact of induced CD4+ T cell-specific ablation of Cxcr5 in SMARTA (SM) cells
ce that had received adoptively transferred naive Cd4-CreERT2+ Cxcr5+/+ SM
LCMV Armstrong and analysis 10 days later. Pre-gated as live CD4+CD45.1/
SGL-1lo or CXCR5SLAMlo cells, CXCR5–PSGL-1hi, CXCR5–SLAMhi, or PSGL-
ion of the results; each symbol represents an individual mouse (n = 4–5).
impact of induced CD4+ T cell-specific ablation of Cxcr5 after NP-KLH/alum
4) from iCxcr5+/+ mice and CXCR5 Tfh cells (CXCR5PD-1hiGITRlo, n = 6) from
d as live CD4+CD19 lymphocytes.
non-Tfh, Tfh, and CXCR5 Tfh cells (columns) sorted as in (D).
criptomes obtained from samples sorted as in (D). Ellipses surrounding the data
EMs in (B).
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Figure 4. Continued T Cell-Specific Bcl6
Expression Is Required for GC Tfh Cell
Maintenance
(A) Schematic representation of the experimental
protocol for the analysis of the impact of induced
CD4+ T cell-specific ablation of Bcl6 at 2 different
time points after s.c. hock immunization with NP-
KLH/alum.
(B) Flow cytometry and quantification of
CXCR5+PD-1lo/int Tfh cells and CXCR5hiPD-1hi GC
Tfh cells from the draining lymph nodes of mice
treated with tamoxifen on days 3 and 4 (upper
panel) or days 6 and 7 (lower panel) and analyzed
on day 14 after immunization, pre-gated as live
CD4+CD44hiCD19 lymphocytes. Right, quantifi-
cation of the results; each symbol represents an
individual mouse (n = 4–7).
(C) Flow cytometry and quantification of Tfh and Tfr
cells in the draining lymph nodes of mice as in (B),
pre-gated as live CD4+CD44hiCD19 lymphocytes.
The gate frequencies indicate the percentage of
CXCR5Foxp3+ Treg cells, CXCR5+Foxp3+ Tfr
cells, and CXCR5+Foxp3 Tfh cells.
*p < 0.05, **p < 0.01 two-tailed nonparametric
Mann-Whitney test (B and C); means ± SEMs in
(B) and (C). See also Figure S2.
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OPEN ACCESSof PD-1 and CXCR5, induced Bcl6 deficiency also resulted in a
reduction of PSGL-1lo cells that are normally representative of
GC Tfh cells (Figures S2D and S2E). Interestingly, when tamox-
ifen was administered on the earlier time point (days 3 and 4),
CXCR5+Foxp3+ Tfr cell frequencies were almost unchanged,
while CXCR5+Foxp3 Tfh cells were strongly diminished, result-
ing in an altered Tfh:Tfr ratio (Figure 4C).
The induced loss of Bcl6 had a strong impact on the GC B cell
response. The frequencies of GC B cells were significantly6 Cell Reports 33, 108232, October 6, 2020decreased in immunized iBcl6D/D mice
as compared to control mice (Figures 5A
and 5B). Similar to the stronger reduction
of Tfh cells that we observed for days 3
and 4 versus days 6 and 7 tamoxifen
treatment, Bcl6 ablation on days 3 and 4
caused a more pronounced decrease in
GC B cell frequencies than tamoxifen
gavage on days 6 and 7 (Figure 5B). While
the total pool of antigen-specific NP+ GC
B cells was not affected in iBcl6D/D mice
in both settings, we observed a defect in
class switching toward IgG1 in the days
3 and 4 tamoxifen administration setting
(Figure 5C). Consequently, the generation
of IgG1+NP+ cells was also impaired in
iBcl6D/Dmice with an ~2.5-fold frequency
decrease as compared to the control
group (Figure 5C). In contrast, T cell-spe-
cific Bcl6 ablation at the peak of the
GC reaction (days 6 and 7 after immuni-
zation) did not cause obvious alterations
in class switching and NP specificity(Figure 5C). The established GC Tfh cells were particularly sensi-
tive to the induced loss of Bcl6 expression, which also impeded
the maintenance of GC B cell frequencies.
Induced Bcl6 Ablation Alters the Ratio of Tfh versus Th1
Cells during Acute Viral Infection
The data from the previous immunization experiments indicated
that Bcl6 expression was particularly vital for GC Tfh cells. To
gain further insight into the role of Bcl6 for Tfh cell maintenance,
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Figure 5. GC B Cell Responses Are Impaired upon the Induced Loss of Bcl6 in CD4+ T Cells
(A) Schematic representation of the experimental protocol for the analysis of the impact of induced CD4+ T cell-specific ablation of Bcl6 at 2 different time points
after s.c. hock immunization with NP-KLH/alum.
(B) Flow cytometry and quantification of IgDloCD95hi GCB cells in the draining lymph nodes of mice treatedwith tamoxifen on days 3 and 4 (upper panel) or days 6
and 7 (lower panel) and analyzed on day 14 after immunization, pre-gated as live CD19+CD4 lymphocytes. Right, quantification of the results; each symbol
represents an individual mouse (n = 4–7).
(C) Flow cytometry and quantification of NP-specific and IgG1+ GC B cells as in (B). The gate frequencies indicate the percentage of IgG1+NP, IgG1+NP+, and
IgG1NP+ GC B cells.
*p < 0.05, **p < 0.01 two-tailed nonparametric Mann-Whitney test (B and C); means ± SEMs in (B) and (C).
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OPEN ACCESSwe conducted cell fate analyses. In contrast to induced Cxcr5
deletion, Bcl6-ablated CD4+ T cells did not exhibit continued
Tfh cell marker expression, thus hampering the tracking of thesecells. To circumvent this issue, we used congenically marked SM
cells of Cd4-CreERT2+Bcl6+/+ and Cd4-CreERT2+Bcl6fl/fl ge-
netic backgrounds to follow the fate of these LCMV-specificCell Reports 33, 108232, October 6, 2020 7
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Figure 6. Induced Bcl6 Ablation Alters the Ratio of Tfh versus Th1 Cells during Acute Viral Infection
(A) Schematic representation of the experimental protocol for the analysis of the impact of induced CD4+ T cell-specific ablation of Bcl6 in SM cells after LCMV
Armstrong infection.
(B) Flow cytometry of splenocytes from tamoxifen-treated wild-type recipients that had received adoptively transferred naive Cd4-CreERT2+ Bcl6+/+ SM and
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(C) Volcano plot of differentially expressed genes between iBcl6+/+ SM and iBcl6D/D SM cells. The relevant genes are indicated. The red dots depict significantly
up- or downregulated genes (adjusted p < 0.1, fold changeR 0.5).
(D) PCA analysis of iBcl6+/+ SM and iBcl6D/D SM cell transcriptomes and signatures of SM iCxcr5+/+ Th1 and Tfh cells from 2 independently performed ex-
periments. Each dot represents donor cells from individual recipient mice. The ellipses surrounding the data points delineate computed confidence ellipses with a
95% confidence level.
*p < 0.05, **p < 0.01 two-tailed nonparametric Mann-Whitney test (B); means ± SEMs in (B).
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OPEN ACCESSCD4+ T cells after transfer into wild-typemice, followed by LCMV
Armstrong infection on day 0 and tamoxifen treatment on days 3
and 4 to ablate Bcl6 (Figure 6A). By day 10 after infection, control
iBcl6+/+ SM cells had differentiated roughly equally into Th1 and
Tfh cell populations (Figure 6B). InducedBcl6 deficiency resulted
in an almost complete loss of CXCR5+ cells and a concomitant
increase in Th1 cell frequencies, while the total number of SM8 Cell Reports 33, 108232, October 6, 2020cells per spleen remained unaltered (Figure 6B). Low SLAM
and PSGL-1 expression levels, which are normally associated
with Tfh cells, were not maintained in the absence of Bcl6 (Fig-
ure 6B). Instead, Bcl6-ablated cells appeared to have regained
the expression of both markers. In fact, the decrease in Tfh cell
numbers was paralleled by an increase in Th1 cell numbers (Fig-
ure 6B). Since total iBcl6D/D SM cell numbers were not changed,
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OPEN ACCESSthis suggested that Th1 cells either compensated for the loss of
Tfh cells through increased proliferation or that Bcl6-ablated
‘‘ex-Tfh’’ cells had adopted a Th1 cell phenotype.
Bcl6 Prevents the Transdifferentiation of Tfh Cells into
Th1 Cells during Acute Viral Infection
To dissect whether iBcl6D/D ex-Tfh SM cells converted into bona
fide Th1 cells or still exhibited a Tfh-like transcriptional program
in the background, we sorted CD45.1/2+ iBcl6+/+ and iBcl6D/D
SM cells for RNA-seq and transcriptomic analyses. Significant
changes in differentially expressed genes between iBcl6+/+ and
iBcl6D/D SM cells revealed many Th1-associated genes being
upregulated in iBcl6D/D SM cells (e.g., GzmB, Id2, Ifngr1,
Ly6c2) (Figure 6C). In contrast, numerous important Tfh cell mol-
ecules, including Cxcr5, Il6ra, Il6st, and Pou2af1 were downre-
gulated. To assess the similarity of the SM iBcl6D/D cells to Th1
cell transcriptomes (Figure 6D), we used Th1 and Tfh signatures
of SM iCxcr5+/+ control cells obtained from a complementary
adoptive transfer experiment (data not shown). Here, we used
PC2 and PC3, since most of the variability represented by the
first principal component was due to batch effects, which is
commonly observed when independently generated RNA-seq
data are compared. The control Th1 and Tfh signatures were
separated and the transcriptomes of Bcl6-sufficient SM cells
were found in between them (Figure 6D), as the cells consisted
of an equal mixture of Th1 and Tfh cells (Figure 6B). The biolog-
ical replicates ofBcl6-ablated SM cells clustered closely with the
Th1 transcriptomes (Figure 6D). This indicated that these cells
did not maintain a Tfh cell transcriptional pattern but instead
had adopted a Th1 cell gene expression program. This sup-
ported our initial hypothesis that the induced loss of Bcl6 in Tfh
cells led to transdifferentiation into Th1 cells. To finally prove
this in vivo, we conducted a retransfer experiment to also
exclude the possibility that Bcl6-ablated cells were lost
during the immune response and were compensated for
by increased Th1 cell expansion. To this end, we first co-trans-
ferred CD45.1/2 Cd4-CreERT2+Bcl6+/+ and CD45.1/1 Cd4-
CreERT2+Bcl6fl/fl SM cells into primary hosts, followed by acute
LCMV Armstrong infection (Figure 7A). Four days later, Th1
(CXCR5–PSGL-1hi) and Tfh (CXCR5+PSGL-1lo) cells from both
genotypes were retransferred into infection-matched secondary
hosts (Figure 7B). Bcl6 was then deleted in the retransferred
iBcl6D/D SM cells with tamoxifen on days 5 and 6 after infection.
iBcl6+/+ SM cells served as controls. The phenotypic stability of
the transferred Th1 and Tfh SM cells was assessed on day 12
post-infection by flow cytometry and revealed that Th1 cells
maintained the CXCR5PSGL-1hiSLAMlo Th1 cell identity
regardless of Bcl6 ablation (Figures 7B and 7C). The majority
of the transferred iBcl6+/+ control SM Tfh cells continued to
display a Tfh phenotype, while ~30% downregulated CXCR5
and gained PSGL-1 expression reminiscent of Th1 cells. In
contrast, the ability of SM Tfh cells, which had been rendered
Bcl6 deficient (iBcl6D/D), to gain Th1 cell marker expression
was strongly increased from ~20% to >70% (Figures 7B and
7C). Nevertheless, the total number of SM cells per spleen was
unaffected by the induced Bcl6 knockout (Figure 7D). Moreover,
Bcl6-ablated cells also expressed higher levels of the Th1-asso-
ciated transcription factor T-bet compared to the Bcl6-sufficientSM control cells (Figure 7E). These data demonstrated that the
loss of Bcl6 in established Tfh cells resulted in a phenotypical
shift toward Th1 surface marker expression, which was under-
lined by the adoption of a Th1-like transcriptional program.
DISCUSSION
Tfh cell differentiation is a multistep process that involves
sequential cognate interactions with DCs and B cells in different
micro-anatomical locations within secondary lymphoid organs
(Crotty, 2019; Qi, 2016; Vinuesa et al., 2016). These processes
are highly regulated on the molecular level by various transcrip-
tion factors and microRNAs (miRNAs) (Maul et al., 2019; Qin
et al., 2018). Until recently, it was difficult to assess the require-
ments of T cell-intrinsic factors that are required for the mainte-
nance of already established Tfh cells. Here, we used temporally
guided ablation of the Tfh cell characteristic genes Cxcr5 and
Bcl6 to systematically assess their requirements for Tfh cell
maintenance. Ablation of Cxcr5 in preexisting Tfh cells showed
minor effects on the identity of these cells and their B cell helper
abilities. In contrast, continued Bcl6 expression in T cells was
critical for the maintenance of GC Tfh and GC B cells. More
important, our data highlighted Bcl6 as a gatekeeper of Tfh cell
plasticity in vivo that limited the transdifferentiation of estab-
lished Tfh cells into Th1 cells during acute viral infection.
Several studies have addressed the requirement of CXCR5
expression by Tfh cells for entering the follicle and induction of
GCs (Ansel et al., 1999; Arnold et al., 2007; Hardtke et al.,
2005; Haynes et al., 2007; Junt et al., 2005). CXCR5-deficient
CD4+ T cells could still mount GC B cell responses, although
the size of GCs was reduced and the frequencies of GC B cells
and class switching were slightly lower (Arnold et al., 2007; Hay-
nes et al., 2007). It should be noted that CXCR5-dependent
follicular recruitment may also be bypassed by some T helper
cells that are passively dragged into the follicle by B cells (Okada
et al., 2005). Interestingly, mice that lack CXCR5+ CD4+ T cells
were completely resistant to collagen-induced arthritis, despite
grossly normal GC formation (Moschovakis et al., 2017). Previ-
ously, it was difficult to assess the role of CXCR5, especially dur-
ing later stages of the GC response due to the lack of conditional
Cxcr5 alleles. Instead, these studies relied either on adoptively
transferred TCR-tg cells or mixed bone marrow chimeras using
CXCR5/ backgrounds. We therefore devised a versatile in vivo
system that allowed us to delete a gene of interest specifically in
CD4+ T cells in a temporally controlled fashion. Using this sys-
tem, we explored the effect of acute ablation of Cxcr5 in settings
of polyclonal as well as antigen-specific TCR-tg CD4+ T cell re-
sponses, with an emphasis on already-established Tfh cells.
Interestingly, Tfh cells that no longer expressed CXCR5 on their
surface were able to sustain the high, Tfh-characteristic protein
expression levels of PD-1 and Bcl6. In addition, the transcrip-
tome of Cxcr5-ablated cells was very similar to that of the
Cxcr5-sufficient control cells. These findings emphasize that
CD4+ T cells can not only circumvent the need of CXCR5 expres-
sion for GC localization (Moriyama et al., 2014) but they also do
not require continued CXCR5 expression to maintain their
phenotype. This is surprising, as GC-localized Tfh cells express
the highest levels of CXCR5, and the binding of CXCL13 inducesCell Reports 33, 108232, October 6, 2020 9
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Figure 7. Bcl6 Prevents the Transdifferentiation of Tfh Cells into Th1 Cells during Acute Viral Infection
(A) Schematic representation of the experimental protocol for the analysis of the impact of induced CD4+ T cell-specific ablation of Bcl6 in SM cells when Tfh and
Th1 cells were first generated through LCMV Armstrong infection and then transferred into pre-infected secondary hosts as depicted prior to Bcl6 ablation.
(B) Flow cytometry of splenocytes from primary and secondary recipients, given adoptive transfers of SM cells. SM Tfh (CXCR5+PSGL-1lo) and SM Th1
(CXCR5PSGL-1hi) cells were sorted from pooled spleens of primary recipient mice on day 4 after i.p. LCMV infection and retransferred into infection-matched
secondary hosts (left panel). On day 12 after infection, the co-transferred Th1 (right panel, upper row) and Tfh cells (right panel, lower row) fromSMCd4-CreERT2+
Bcl6+/+ and SM Cd4-CreERT2+ Bcl6fl/fl mice were quantified. The gate frequencies indicate the percentage of CXCR5PSGL-1hi Th1 and CXCR5+PSGL-1lo Tfh
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(C and D) Quantification of the results depicted in (B); each symbol represents an individual mouse (n = 6–7).
(E) Flow cytometric analysis and quantification of T-bet expression in co-transferred SMTfh cells analyzed on day 12 post-infection as in (B). ‘‘Endogenous’’ refers
to polyclonal CD4+ T cells of the infected secondary host mice.
*p < 0.05, **p < 0.01 two-tailed nonparametric Mann-Whitney test (C and D); paired t test (E); means ± SEMs in (C) and (D).
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OPEN ACCESSphosphatidylinositol 3-kinase (PI3K)-Akt signaling (Shi et al.,
2018), which is essential for Tfh cells (Rolf et al., 2010).
Although CXCR5 overexpression promotes enhanced GC local-
ization (Shi et al., 2018), CXCR5-deficient CD4+ T cells were
shown to still enter GCs, however, with reduced LZ polarization
(Greczmiel et al., 2017; Haynes et al., 2007). This was associated10 Cell Reports 33, 108232, October 6, 2020with impaired affinity maturation toward epitopes of LCMV
(Greczmiel et al., 2017). Therefore, it is conceivable that
CXCR5 on T cells functions to first efficiently recruit T cells to
the GC and then confine T cell help and hence selection of
high-affinity GC B cells to the LZ, without affecting T cell-intrinsic
properties.
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OPEN ACCESSA possible disentanglement of the Tfh cell phenotype and
CXCR5 expression was also recently suggested by the observa-
tion of peripheral PD-1hiCXCR5 Tfh-like cell populations with B
cell helper abilities and Tfh cell marker expression patterns, for
example, in the joints of rheumatoid arthritis patients and in tu-
mors of cancer patients, although their ontogeny and function
remain largely elusive (Gu-Trantien et al., 2017; Rao et al.,
2017). The fact that many aspects of the GC B cell response
were not altered by CD4+ T cell-specific Cxcr5 ablation raises
the question of how CXCR5 Tfh cells manage to retain their
GC localization. In our RNA-seq data, we could not find a
compensatory upregulation of migratory modules upon the
loss of CXCR5. A previous report showed that CXCR5 and
S1PR2 have somewhat overlapping functions, and only CD4+
T cells deficient for both factors lost the capacity to enter GCs
(Moriyama et al., 2014). Similar to control Tfh cells, Cxcr5-abla-
ted Tfh cells in our experiments showed the continued expres-
sion of S1pr2 and simultaneous downregulation of Gpr183,
which encodes EBI2. Recently, Vanderleyden et al. (2020)
showed that Tfr cells do not depend on CXCR5 to acquire and
maintain GC localization, which complements our findings on
the requirements of CD4+ T cell-expressed CXCR5 for Tfh cell
and GC maintenance.
The slight increase in IgG1+ GCB cells that we observed in our
inducible CD4+ T cell-specific Cxcr5 deletion system stands in
contrast to data from a study that used Cxcr5/ CD4+ T cells
and reported impaired class switching (Arnold et al., 2007). Class
switching has recently been shown to be an early event that is
initiated before GC formation, when activated T cells interact
with primed B cells at the T:B zone border (Roco et al., 2019).
If CD4+ T cells lack CXCR5 expression during this early phase,
Tfh cell migration toward the B cell follicle may be less efficient
and thus curtails class switching, whereas the deletion of
CXCR5 at later stages could have less adverse effects.
The importance of Bcl6 expression for the induction of Tfh cell
differentiation is well established (Hollister et al., 2013; Johnston
et al., 2009; Nurieva et al., 2009; Poholek et al., 2010; Yu et al.,
2009). One of the main functions of Bcl6 is the inhibition of the
Tfh cell antagonist Blimp-1 (Johnston et al., 2009). As Tfh cells
are completely absent in mice with a conditional knockout of
Bcl6 in CD4+ T cells, it was thus far not possible to easily address
the role of Bcl6 beyond Tfh cell induction. Evidence for the func-
tion of Bcl6 in mature Tfh cells comes from chromatin immuno-
precipitation sequencing (ChIP-seq) experiments that mapped
the genomic occupancy at numerous genes relevant to Th1,
Th2, and Th17 differentiation pathways (Hatzi et al., 2015; Liu
et al., 2016), indicating a role for Bcl6 in preventing alternative
cell fate programs. However, it has not been investigated before
by detailed loss-of-function studies whether Bcl6 is required for
the identity and function of fully matured Tfh cells. In our exper-
iments, we found that GC Tfh cells, which express the highest
levels of Bcl6, were particularly sensitive toward Bcl6 ablation,
while Bcl6int Tfh cells were only moderately affected. In GCs,
Tfh cells must adapt to conditions such as hypoxia (Zhu et al.,
2019), restricted localization within the LZ (Fuller et al., 1993;
Haynes et al., 2007), and high concentrations of the antagonistic
cytokine IL-2 (Papillion et al., 2019). High levels of Bcl6 may
therefore be required to maintain GC localization by repressingseveral T cell zone migratory molecules such as CCR7 and
PSGL-1 or chemotactic receptors responding to cues outside
theGC, such as S1PR1 and EBI2 (Hatzi et al., 2015). More impor-
tant, through the inhibition of other T helper cell programs, Bcl6
may enable Tfh cells to withstand non-Tfh cell cues, for example,
IL-2 and interferon-g (IFN-g). Outside the GC, however, Tfh cells
may not equally rely on Bcl6. Despite the collapse of the GC Tfh
cell population upon Bcl6 ablation, the frequencies of GC B cells
were not similarly affected in our experiments, and a small but
stable GC B cell population was maintained over time.
CXCR5+PD-1int/lo cells may be able to take over some of the
functions of GC Tfh cells; however, these cells were not able to
sustain normal frequencies of class-switched IgG1+ GC B cells.
Tfr cells share the expression of molecules that are normally
associated with Tfh and Treg cells, as well as several molecular
requirements for Tfh cell differentiation, such as co-stimulation
and interactions with B cells (Chung et al., 2011; Linterman
et al., 2011). Despite these striking similarities, we observed
that Tfr cells were not equally affected by an induced loss of
Bcl6. Moreover, when Bcl6was deleted at early time points after
immunization, Tfr cell frequencies were largely unaltered. This is
unexpected, as Tfr cells are unable to form in Foxp3Cre Bcl6fl/fl
mice (Botta et al., 2017; Fu et al., 2018; Wu et al., 2016). Never-
theless, Bcl6 expression is lower in Tfr cells relative to Tfh cells
(Chung et al., 2011) and may be dispensable after Tfr cell devel-
opment. It is also possible that despite a normal phenotype, Tfr
cells in inducedBcl6-deficientmicemay be functionally impaired
and contribute to the defects observed in the GC response. It
was recently shown that in the absence of Tfr cells, Tfh cells
adopt a cytotoxic phenotype and appear to induce apoptosis
in GC B cells (Xie et al., 2019). This could be an additional expla-
nation for the reduced GC B cell frequencies in our system.
Plasticity among CD4+ T helper cells is a widely accepted
concept (DuPage and Bluestone, 2016; O’Shea and Paul,
2010), and several lines of evidence also point to the extensive
plasticity of Tfh cells (Cannons et al., 2013). For example,
in vitro-generated Tfh-like cells could be polarized to increase
Th1, Th2, or Th17 cytokine expression (Lu et al., 2011). The
loss of the miR-17-92 cluster in LCMV-specific SM cells resulted
in the co-expression of a Th17 gene expression program that
was layered on top of the Tfh cell program (Baumjohann et al.,
2013a). Another study found that Tfh cells gave rise to patho-
genic Th2 cells in an allergy model (Ballesteros-Tato et al.,
2016). Our finding that Bcl6 ablation in Tfh cells during LCMV
Armstrong infection resulted in an increased plasticity toward
Th1 cells expands the view of Bcl6 as a critical inhibitor of alter-
native T cell fates to already-established Tfh cells. The compat-
ibility of Th1 and Tfh cell programs has been suggested by the
co-expression of Bcl6 and T-bet in certain contexts, and Bcl6+
Tfh cells may also represent a transitional differentiation state
or may serve as precursors for other effector cells (Sheikh et
al., 2019; Baumjohann et al., 2011; Nakayamada et al., 2011;
Oestreich et al., 2011; Weinstein et al., 2018; Yusuf et al.,
2010). In our experiments, upon induced Bcl6 ablation, LCMV-
specific SM cells lost the characteristic surface marker expres-
sion of Tfh cells and downregulated Tfh cell-associated
transcripts, including Il6ra and Il6st. The loss of the Tfh cell
phenotype and the propensity to adopt a Th1 cell phenotype inCell Reports 33, 108232, October 6, 2020 11
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OPEN ACCESSour temporally controlled Bcl6 ablation system may be addition-
ally explained by the findings of a recent study, in which IL-6
signaling during a viral infection was reported to shield Tfh cells
from abundant IL-2 signals, which destabilize the Tfh cell pheno-
type (Papillion et al., 2019). Bcl6 expression in T cells has been
previously shown to be required for the generation of Tfh cell-
derived memory cells, in particular, of the central memory
phenotype (Choi et al., 2013; Ichii et al., 2007; Kitano et al.,
2011; Liu et al., 2012; Pepper et al., 2011). In this regard, our find-
ings are in line with a study that showed a decrease in Tfh mem-
ory cells upon induced Bcl6 deletion (Ise et al., 2014). Interest-
ingly, the loss of Tfh cell identity that we observed following
induced Bcl6 ablation in CD4+ T cells resembles the rapid loss
of the Tfh cell phenotype that was also described when T-B
cell interactions were disrupted by the blockade of CD40:CD40L
and ICOSL:ICOS pathways during ongoing GC responses
following protein immunization (Baumjohann et al., 2013b).
This is relevant, since ICOS signaling promotes Bcl6 expression
for Tfh cell differentiation (Choi et al., 2011), and ICOS is impor-
tant for Tfh cell maintenance (Akiba et al., 2005; Weber et al.,
2015). Our data indicate that when strong cues for other cell
fate programs are present (e.g., predominant Th1-polarization
during LCMV infection), Tfh cells are highly dependent on Bcl6
to prevent transdifferentiation into other T helper cell subsets,
thus highlighting the plasticity of Tfh cells.
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Fluoromount G Thermo Fisher Scientific Cat# 00-4958-02
Guanidine hydrochloride Sigma-Aldrich Cat# G3272
Maxima H Minus Reverse Transcriptase Thermo Fisher Scientific Cat# EP0753
(Continued on next page)
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NP24-KLH or 4-hydroxy-3-
nitrophenylacetyl conjugated to keyhole
limpet hemocyanin
Biosearch Technologies Cat# N-5060
Proteinase K solution Ambion Cat# AM2546
Streptavidin-APC BioLegend Cat# 405207
Streptavidin-PE BioLegend Cat# 405204
Tamoxifen Sigma-Aldrich Cat# T5648
Taq Polymerase NEB Cat# M0273S
Terra PCR Direct Polymerase Mix Takara Bio Cat# 639287
UltraPure DNase/RNase-Free Distilled
Water
Thermo Fisher Scientific Cat# 10977-049
Critical Commercial Assays
CD4+ T cell Isolation Kit, mouse Miltenyi Biotech Cat# 130-104-454
CleanNGS CleanNA Cat# CNGS-0050
EasySep Mouse Naive CD4+ T cell Isolation
Kit
STEMCELL Technologies Cat# 19765
Foxp3 / Transcription Factor Staining buffer
set
Thermo Fisher Scientific Cat# 00-5523-00
High Sensitivity DNA Analysis Kits Agilent Technologies Cat# 5067-4626
Nextera XT DNA Sample Preparation Kit Illumina Cat# FC-131-1024 and Cat# FC-131-1001
SensiFAST Probe No-ROX One-Step Kit Bioline Cat# BIO-76001
Deposited Data
RNA-Sequencing data This work GEO: GSE142229
Experimental Models: Organisms/Strains
Bcl6fl/fl (Bcl6tm1.1Dent) The Jackson Laboratory JAX #023727
C57BL/6 Charles River or Janvier Laboratories n/a
CD45.1 (Ptprca Pepcb/BoyJ) The Jackson Laboratory JAX #002014
Cd4-CreERT2 knock-in (CD4tm1(CreERt2)ThBu) Sledzinska et al., 2013 n/a
Cxcr5fl/fl (Cxcr5tm1.Namt) Bradford et al., 2017 n/a
Rosa26fl-Stop-fl-eYFP (Gt(ROSA)
26Sortm1(eYFP)Cos)
The Jackson Laboratory JAX #006148
SMARTA (Tg(TcrLCMV)Aox) Oxenius et al., 1998 n/a
B6.Cg-Cd4tm1(cre/ERT2)Thbu-Cxcr5tm1.Namt This work n/a
B6.Cg-Tg(TcrLCMV)Aox-Ptprca Pepcb-
Cd4tm1(cre/ERT2)Thbu
This work n/a
B6.Cg-Tg(TcrLCMV)Aox-Ptprca Pepcb-
Cd4tm1(cre/ERT2)Thbu-Cxcr5tm1.1Namt
This work n/a
B6.Cg-Cd4tm1(cre/ERT2)Thbu-Gt(ROSA)
26Sortm1(EYFP)Cos
This work n/a
B6.Cg-Cd4tm1(cre/ERT2)Thbu-Bcl6tm1.1Dent-
Gt(ROSA)26Sortm1(EYFP)Cos
This work n/a
B6.Cg-Tg(TcrLCMV)Aox-Ptprca Pepcb-
Cd4tm1(cre/ERT2)Thbu-Gt(ROSA)
26Sortm1(EYFP)Cos
This work n/a
B6.Cg-Tg(TcrLCMV)Aox-Ptprca Pepcb-
Cd4tm1(cre/ERT2)Thbu- Bcl6tm1.1Dent-Gt(ROSA)
26Sortm1(EYFP)Cos
This work n/a
Oligonucleotides
PrimeTime Assay Bcl6 IDTDNA Mm.PT.58.1178966; FAM
PrimeTime Assay Actb IDTDNA Assay ID: Mm.PT.58.33257376.gs; HEX
(Continued on next page)
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Bcl6 gDNA F
(ACCACTGACCCAGAGGATTA)
IDTDNA Custom
Bcl6 gDNA R
(GCTTCAAATCCCAGCAAAGG)
IDTDNA Custom
CXCR5 gDNA F
(ACATCCTGGTGCTGGTAATC)
IDTDNA Custom
CXCR5 gDNA R
(ACTAAGAGAAGGTCGGCTACT)
IDTDNA Custom
Software and Algorithms
FlowJo software https://www.flowjo.com/ RRID:SCR_008520
GraphPad Prism 8 https://www.graphpad.com/ RRID:SCR_002798
Cowplot Love et al., 2014 RRID:SCR_018081
Ggplot2 Wickham, 2016 RRID:SCR_014601
ImageJ https://imagej.net/Welcome RRID:SCR_003070
Light Cycler 480 SW 1.5.1 Roche RRID:SCR_012155
STAR 2.6.0a https://github.com/alexdobin/STAR RRID:SCR_015899
zUMIS https://github.com/sdparekh/zUMIs RRID:SCR_016139
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dirk
Baumjohann (dirk.baumjohann@uni-bonn.de).
Materials Availability
This study generated several mouse strains by intercrossing various commercially and non-commercially available mouse strains.
There are restrictions to the availability of the generated strains as some of the original strains were obtained under material transfer
agreement that do not permit redistribution of these strains without prior permission of the strain owner.
Data and Code Availability
Source transcriptomic data are available through GEO: GSE142229. Other source data are available from the Lead Contact upon
reasonable request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cd4-CreERT2 knock-in (C57BL/6-CD4tm1(CreERt2)ThBu) mice (Sledzinska et al., 2013) and Cxcr5fl/fl (Cxcr5tm1.Namt) mice (Bradford et al.,
2017) have been described previously.Bcl6fl/fl (Bcl6tm1.1Dent, stock number 023727) andRosa26fl-Stop-fl-YFP (Gt(ROSA)26Sortm1(EYFP)Cos,
stock number 006148) mice were purchased from The Jackson Laboratory. For adoptive transfer experiments, compoundmouse lines
were further intercrossed with LCMV GP61-80 peptide-specific SMARTA TCR-tg mice (Oxenius et al., 1998) and congenic CD45.1 al-
leles. Wild-type C57BL/6 mice were purchased from Charles River or Janvier Labs. All Mice were housed under specific pathogen
free conditions in individually ventilated cages and all animal experiments were performed in accordance with European Regulation
and Federal Law and approved by the Regierung von Oberbayern. All mice used for experiments were used at 8-12 weeks of age.
Experimental groups were sex and age-matched. To better reveal the dynamic range of the gene ablation effects, our approved animal
protocol containing limited numbers of experimental animals focused on testing a wide range of different tamoxifen application and
analysis time points as well as independently reproducing the results in two different experimental systems with sufficient numbers
of animals, instead of performing extensive repetition experiments for only a few time points.
METHOD DETAILS
Immunizations, adoptive cell transfers, immunizations, infections, and tamoxifen treatment
For immunizations, 4-hydroxy-3-nitrophenylacetyl conjugated to keyhole limpet hemocyanin (NP24-KLH, Biosearch Technologies)
dissolved in PBS was mixed 1:1 with alum (Imject Alum, Thermo Scientific) and rotated for 45 min at room temperature prior toCell Reports 33, 108232, October 6, 2020 e3
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using an insulin syringe (BD Biosciences). Adoptive cell transfers of SMARTA cells into wild-type hosts were performed as previously
described (Baumjohann et al., 2013a). In brief, naive CD4+ T cells were isolated from spleens and LNs of SMARTAmice through nega-
tive selection using the EasySep Mouse Naive CD4 T cell isolation kit (StemCell Technologies). For most experiments, 1x104 naive
SMARTA cells were adoptively transferred in PBS into wild-type recipients by tail vein injection, followed by i.p. injection of 2x105 pfu
LCMV Armstrong. Tamoxifen-induced ablation experiments were performed with Cd4-CreERT2 knock-in mice as previously
described (Zeitrag et al., 2020). In brief, tamoxifen (1g, Sigma-Aldrich) was dissolved in 100% Ethanol (1ml). 29ml corn oil (Sigma-
Aldrich) were added and the mixture was incubated in a water bath at 56C until the solid tamoxifen was fully dissolved. Aliquots
of the 33.3 mg/ml stock solution were stored at 20C until further use. Mice received a dose of 5 mg tamoxifen in 150 ml volume
by intragastric gavage twice daily on two consecutive days (either day 3 and 4 or day 6 and 7 after immunization). For the retransfer
experiment, 0.5x106 naive SMARTA cells were adoptively transferred into wild-type mice one day prior to infection with 1x106 pfu
LCMV Armstrong. Tfh and Th1 cells derived from the transferred CD45.1/2 Cd4-CreERT2+Bcl6+/+ and CD45.1/1 Cd4-CreER-
T2+iBcl6fl/fl SMARTA cells were sorted as CXCR5+PSGL-1lo and CXCR5–PSGL-1hi, respectively, into PBS + 2% FCS, washed,
and counted. 2x104 Th1 or Tfh cells from both genotypes were then co-transferred into infection-matched secondary wild-type
hosts. Recipients were gavaged with tamoxifen one and two days after the re-transfer.
Flow cytometry
General guidelines for the use of flow cytometry and cell sorting in immunological studies were followed (Cossarizza et al., 2019).
Single-cell suspensions from spleen or peripheral lymph nodes were prepared by mincing the tissue between the frosted ends of
glass slides. Dead cells were excluded with 7-AAD (eBioscience/Thermo Fisher) for surface maker analyses or with the fixable
viability dye eFluor 780 (eBioscience/Thermo Fisher) for intracellular analyses. Before staining of surface/intracellular molecules,
Fc receptors were blocked by preincubation of cells with anti-CD16/32 (clone 93; Biolegend) and 1% mouse/rat serum (StemCell
Technologies). The following antibodies were used for analyses by flow cytometry: CD4 (RM4-5, BD Biosciences, BioLegend),
CD45.2 (104, BD Biosciences, eBioscience), CD86 (GL1, BD Biosciences, Biolegend); CD19 (6D5), CD44 (IM7), CD45.1 (A20),
PD-1 (29F.1A12), SLAM (TC15-12F12.2) (all Biolegend); Fas (Jo2), GITR (DTA-1), IgG1 (A85-1), PSLG-1 (2PH1) (all BD Bioscience);
CXCR4 (2B11), PD-1 (J43), IgD (11-26c) (all eBioscience). CXCR5 was stained with biotinylated anti-CXCR5 (clone L138D7 from
Biolegend) for 30min on ice, followed by washing and incubation with streptavidin conjugated to APC or PE (Biolegend) for 15min
on ice (Baumjohann and Ansel, 2015). Intracellular transcription factor stainings were performed with the Foxp3 Staining Set from
eBioscience using the following fluorophore-coupled mAbs: Bcl6 (K112-91, BD Biosciences), T-bet (4B10, BioLegend) and Foxp3
(FJK-16 s, eBioscience). NP-PE (4-Hydroxy-3-nitrophenylacetyl hapten conjugated to phycoerythrin) was purchased fromBiosearch
Technologies (conjugation ratio 28:1). Samples were acquired on a three-laser BD FACS Canto II or a 5-laser BD LSRFortessa using
BD FACSDiva software. Cell sorting was performed on a BD FACSAriaFusion. Data were analyzed with FlowJo software (Treestar).
Quantitative RT-PCR analysis
RT-qPCR was used to quantify deletion efficiency of Bcl6 genomic DNA und mRNA. 200-500 CXCR5+ PD-1+ cells were sorted into a
96-well qPCR plate (Roche Diagnostics) containing 5 ml lysis buffer consisting of a 1:500 dilution of Phusion HF buffer (New England
Biolabs) in nuclease freewater (Thermo Fisher). Cellular components were removed by proteinase K (Ambion) digest for 10minutes at
55C, followed by desiccation at 95C for 10 minutes without a seal to reduce the volume and inactivate proteinase K. RNA was sub-
sequently transcribed into cDNA using the SensiFast One-Step Real-Time RT-PCR kit (Bioline). The expression of Bcl6 mRNA was
measured bymultiplexed qRT-PCR using PrimeTime gene expression probes (IDTDNA) forBcl6 (Mm.PT.58.11789661; FAM) and the
housekeeper Actb (Mm.PT.58.33257376.gs; HEX). For the quantification of Bcl6 gDNA, the reverse transcriptase step was omitted
and custom PrimeTime probes (IDTDNA) for genomic Bcl6 (F: ACCACTGACCCAGAGGATTAFAM; R: GCTTCAAATCCCAG
CAAAGG; FAM) and the control gene Cxcr5 (F: AACATCCTGGTGCTGGTAATC; R: ACTAAGAGAAGGTCGGCTACT; HEX) were
used. The expression was measured on a Light Cycler 480II (Roche) device with the Light Cycler 480 SW 1.5.1 software.
RNA-sequencing
For RNA-seq analysis, 1,000-2,000 Tfh or non-Tfh cells were sorted into a 96-well plate containing 50 ml lysis buffer using a
FACSAriaFusion cell sorter (BD Biosciences). The lysis buffer consisted of 5 M Guanidine hydrochloride (Sigma-Aldrich), 1% 2-mer-
captoethanol (Sigma-Aldrich) and a 1:500 dilution of Phusion HF buffer (New England Biolabs). After sorting the cells were briefly
centrifuged and immediately frozen on dry ice. cDNAwas then generated using amodified version of the single cell RNA-seq protocol
mcSCRB (Bagnoli et al., 2018). cDNA was tagmented with the Nextera XT DNA Library Prep Kit (Illumina) using 0.8 ng as input. Li-
braries were paired-end sequenced on high output flow cells of an Illumina HiSeq 1500 instrument at LAFUGA Genomics of LMU
Munich’s Gene Center. Sixteen bases were sequenced with the first read to obtain cellular and molecular barcodes and 50 bases
were sequenced in the second read into the cDNA fragment. An additional 8 bp bases were sequenced to obtain the i7 barcode.
All raw fastq data were processed with zUMIs (Parekh et al., 2018) and mapped to the mouse genome (mm10) using STAR 2.6.0a
(Dobin et al., 2013). Gene annotations were obtained from Ensembl (GRCm38.75). Samples were identified via the i7 and Cellular
Barcode or only the i7 barcode, with initial phred score filtering allowing 2 or 1 bases below 20, respectively. UMI phred filtering al-
lowed 2 bases below 20. After initial data processing, generated countmatrices were loaded into R.We filtered out sparsely detectede4 Cell Reports 33, 108232, October 6, 2020
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(Love et al., 2014). Hierarchical clustering for marker gene expression was performed using Complex Heatmaps. Differentially ex-
pressed genes were called with DESeq2. All plotting was performed using ggplot2 and cowplot.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed with Prism 8 (GraphPad) and are specified in each corresponding figure legend.Cell Reports 33, 108232, October 6, 2020 e5
